Q: We are using a biosimilar for infliximab but it is manufactured by Merck/Samsung rather than Pfizer/Hospira. CMS requires that a manufacturer specific modifier be appended to the HCPCS code. Is there a new one for Merck/Samsung?
Q: For a ureteroscopy intended as a procedure with a biopsy and double-J stent, if the procedure ends when only the scope was placed before a biopsy was taken, could you just code ureteroscopy instead of coding it with the biopsy and the modifier -74?
Q: A clinic employee is being seen as a patient of the clinic for additional vaccinations. The medical assistant rooming the patient wants to review the vaccination history. Is this a HIPAA violation?
